Uenaka T - Search Results

1

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.

Yamada K, Hori Y, Inoue S, Yamamoto Y, Iso K, Kamiyama H, Yamaguchi A, Kimura T, Uesugi M, Ito J, Matsuki M, Nakamoto K, Harada H, Yoneda N, Takemura A, Kushida I, Wakayama N, Kubara K, Kato Y, Semba T, Yokoi A, Matsukura M, Odagami T, Iwata M, Tsuruoka A, Uenaka T, Matsui J, Matsushima T, Nomoto K, Kouji H, Owa T, Funahashi Y, Ozawa Y. Yamada K, et al. Among authors: uenaka t. Cancer Res. 2021 Feb 15;81(4):1052-1062. doi: 10.1158/0008-5472.CAN-20-0782. Epub 2021 Jan 6. Cancer Res. 2021. PMID: 33408116

2

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.

Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M. Matsui J, et al. Among authors: uenaka t. Int J Cancer. 2008 Feb 1;122(3):664-71. doi: 10.1002/ijc.23131. Int J Cancer. 2008. PMID: 17943726 Free article.

3

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.

Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A. Watanabe Miyano S, et al. Among authors: uenaka t. Mol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535969

4

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Matsui J, et al. Among authors: uenaka t. Clin Cancer Res. 2008 Sep 1;14(17):5459-65. doi: 10.1158/1078-0432.CCR-07-5270. Clin Cancer Res. 2008. PMID: 18765537

5

Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.

Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y. Ito K, et al. Among authors: uenaka t. Cancer Sci. 2014 Aug;105(8):1023-31. doi: 10.1111/cas.12450. Cancer Sci. 2014. PMID: 24841832 Free PMC article.

6

Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.

Asano M, Matsui J, Towle MJ, Wu J, McGonigle S, DE Boisferon MH, Uenaka T, Nomoto K, Littlefield BA. Asano M, et al. Among authors: uenaka t. Anticancer Res. 2018 Jun;38(6):3375-3385. doi: 10.21873/anticanres.12604. Anticancer Res. 2018. PMID: 29848686

7

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.

Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H. Knutson SK, et al. Among authors: uenaka t. Mol Cancer Ther. 2014 Apr;13(4):842-54. doi: 10.1158/1535-7163.MCT-13-0773. Epub 2014 Feb 21. Mol Cancer Ther. 2014. PMID: 24563539

8

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Nakamura K, et al. Among authors: uenaka t. Mol Cancer Ther. 2002 Jan;1(3):169-75. Mol Cancer Ther. 2002. PMID: 12467211

9

A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.

Nakamura K, Uenaka T, Nagasu T, Sugumi H, Yamaguchi A, Kotake Y, Okada T, Kamata J, Niijima J, Taniguchi T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Nakamura K, et al. Among authors: uenaka t. Cancer Sci. 2003 Jan;94(1):119-24. doi: 10.1111/j.1349-7006.2003.tb01362.x. Cancer Sci. 2003. PMID: 12708485 Free article.

10

Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities.

Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M. Mizui Y, et al. Among authors: uenaka t. J Antibiot (Tokyo). 2004 Mar;57(3):188-96. doi: 10.7164/antibiotics.57.188. J Antibiot (Tokyo). 2004. PMID: 15152804 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page